ReSPOnD (Retrospective Study of Patient Outcomes Following ARCADIAN)
Research type
Research Study
Full title
A retrospective analysis of outcome data of patients following the ARCADIAN (Atovaquone with Radical ChemorADIotherapy in locally Advanced NSCLC) trial.
IRAS ID
335371
Contact name
Geoff Higgins
Contact email
Sponsor organisation
University of Oxford
Clinicaltrials.gov Identifier
266541, ARCADIAN reference number
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
Summary of Research
This work will retrospectively analyse patient data from the ARCADIAN trial. This will involve using NHS England and NHS Scotland to access patient data via the National Cancer Registration Dataset and Hospital Episode Statistics. This will allow us to access data including patient mortality at 6 months and 12 months after the post-treatment 6 month follow up and tumour recurrence, new cancer diagnoses, additional non-cancer diagnoses post-treatment completion and participant hospitalisation after the post-treatment 6 month follow up. This will provide further understanding of the effects of atovaquone given alongside a chemoradiotherapy treatment regimen for non-small cell lung cancer that has spread locally and has a hypoxic (low oxygen) environment.
Summary of Results
This study looked at how patients from the phase I ARCADIAN trial did over time. In this trial, people with non-small cell lung cancer were treated with atovaquone together with standard chemotherapy and radiation. Nineteen patients took part. Their median overall survival was 36 months, meaning half of the patients lived longer than three years after starting treatment. Overall, their results were similar to or better than those seen in other studies using chemoradiotherapy for this type of lung cancer. More details will be shared in the upcoming ARCADIAN research paper.REC name
HSC REC A
REC reference
24/NI/0054
Date of REC Opinion
16 Apr 2024
REC opinion
Favourable Opinion